On April 8, 2015, a motion for relief from the automatic stay was filed in the bankruptcy case of Dendreon Corporation and its affiliates.
The filing was assigned docket number 558 and is described on the court’s official docket as follows:
Motion for Relief from Stay / Motion of GlaxoSmithKline LLC for Relief from the Automatic Stay Under Bankruptcy Code Section 362(d)(1) . Fee Amount $176. Filed by GlaxoSmithKline LLC. Hearing scheduled for 4/29/2015 at 10:00 AM at US Bankruptcy Court, 824 Market St., 6th Fl., Courtroom #2, Wilmington, Delaware. Objections due by 4/22/2015. (Attachments: # (1) Notice # (2) Exhibit A # (3) Exhibit B # (4) Exhibit C # (5) Proposed Form of Order) (Patterson, Morgan)
Dendreon Corporation filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on November 10, 2014. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Delaware. The case number for the lead bankruptcy case is 14-12515. The bankruptcy case is currently assigned to United States Bankruptcy Judge Peter Walsh. The law firm of Skadden, Arps, Slate, Meagher & Flom LLP is acting as lead bankruptcy counsel to Dendreon Corporation in the bankruptcy case.